Lipocine announced the dosing of the first participant in its BLOOM Phase 3 trial for postpartum depression; the 48-hour oral treatment aims for at-home use, with topline results expected in 2H 2027.
Lipocine announced the dosing of the first participant in its BLOOM Phase 3 trial for postpartum depression; the 48-hour oral treatment aims for at-home use, with topline results expected in 2H 2027.